ISL2 Antibody

What is ISL2 and why is it important to study in neuroscience research?

ISL2 is a LIM-homeodomain transcription factor with a canonical protein length of 359 amino acid residues and a molecular weight of approximately 39.8 kDa in humans . It functions primarily in the nucleus and plays a crucial role in defining motoneuron subclasses and guiding axon pathways during neural development . ISL2 helps researchers understand developmental neurobiology, particularly the mechanisms underlying motor neuron differentiation, columnar organization, and axonal projection patterns. Studying ISL2 expression provides insights into neural circuit formation and potentially contributes to understanding motor neuron diseases.

Which applications are most appropriate for ISL2 antibody-based research?

ISL2 antibodies can be utilized in multiple experimental applications with varying effectiveness:

The most reliable application appears to be Western blotting, with immunofluorescence also being well-validated for investigating nuclear ISL2 expression patterns .

How specific are available ISL2 antibodies, particularly regarding cross-reactivity with ISL1?

ISL2 shares significant sequence homology with ISL1, creating specificity challenges. Based on available data, specificity varies significantly between antibodies:

• Monoclonal antibodies like 39.4D5 recognize both ISL1 and ISL2, as they target conserved regions

• Antibodies raised against N-terminal regions tend to show higher specificity as these domains differ more between ISL1 and ISL2

• Polyclonal antibodies may exhibit greater cross-reactivity unless specifically isolated against unique epitopes

For experiments requiring ISL2-specific detection, selecting antibodies targeting non-conserved regions and validating specificity with knockout controls is essential .

How should researchers validate ISL2 antibodies before experimental use?

Robust validation follows the "five pillars" approach recommended by the International Working Group for Antibody Validation :

• Genetic strategies: Use ISL2 knockout/knockdown cell lines or tissues as negative controls to verify specificity

• Orthogonal strategies: Compare antibody results with antibody-independent methods (e.g., RNA-seq or mass spectrometry)

• Independent antibody strategies: Utilize multiple antibodies targeting different ISL2 epitopes to confirm specificity

• Recombinant strategies: Overexpress ISL2 in cells with low endogenous expression

• Immunocapture MS strategies: Use mass spectrometry to identify proteins captured by the antibody

For ISL2 antibodies, the genetic strategy using knockout controls provides the highest confidence in specificity .

What controls are essential for rigorous ISL2 antibody experiments?

Every ISL2 antibody experiment should include the following controls:

• Positive controls:

  • Cell lines with confirmed ISL2 expression (HUVEC, HeLa, 293T cells)

  • Tissues known to express ISL2 (developing spinal cord, dorsal root ganglia)

• Negative controls:

  • ISL2 knockout or knockdown cells/tissues

  • Primary antibody omission

  • Isotype controls (especially for flow cytometry)

• Specificity controls:

  • Peptide competition assays

  • Parallel testing with ISL1 knockouts to assess cross-reactivity

  • Secondary antibody-only controls

The inclusion of both positive and negative controls helps to validate experimental procedures and distinguish true signals from artifacts .

How should experimental design differ when studying ISL2 in various species?

When studying ISL2 across species, researchers must consider several factors:

• Sequence homology: Verify antibody epitope conservation in target species

  • Human ISL2 shows 100% sequence identity in immunogen regions with mouse and rat orthologs

  • Additional confirmed reactivity in zebrafish, chicken, and other vertebrates

• Expression patterns: Account for species-specific ISL2 expression patterns

  • Expression timing differences during neural development

  • Distinct columnar organization patterns

• Control selection: Use species-appropriate positive and negative controls

  • Tissue/cells known to express ISL2 in that particular species

  • Species-matched knockout models when available

• Application optimization: Adjust protocols for species-specific tissues

  • Fixation differences (e.g., paraformaldehyde works well across species)

  • Antigen retrieval may need optimization for different tissue densities

  • Different antibody dilutions may be required for optimal signal-to-noise ratio

What are common causes of false positive or false negative results in ISL2 antibody experiments?

Several factors can contribute to unreliable results in ISL2 antibody experiments:

False Positives (Non-specific signals):

• Cross-reactivity with ISL1 or other LIM-homeodomain proteins

• Excessive antibody concentration leading to non-specific binding

• Insufficient blocking or washing steps

• Inappropriate fixation disrupting epitope structure

• Endogenous peroxidase or fluorescent activity in tissues

False Negatives (Lack of detection):

• Epitope masking due to protein-protein interactions

• Improper sample preparation (particularly nuclear extraction for ISL2)

• Insufficient antigen retrieval in fixed tissues

• Inadequate permeabilization limiting antibody access to nuclear ISL2

• Degraded antibody or target protein

To minimize these issues, careful optimization of antibody concentration, blocking conditions, and sample preparation protocols is essential.

How can researchers interpret multiple bands on Western blots using ISL2 antibodies?

Multiple bands on Western blots can have several explanations:

• Protein isoforms: Check databases for known ISL2 splice variants

• Post-translational modifications: Phosphorylation, ubiquitination, etc. may alter mobility

• Degradation products: Incomplete protease inhibition during sample preparation

• Cross-reactivity: Particularly with ISL1 (~39.1 kDa vs. ISL2 ~39.8 kDa)

• Non-specific binding: Interaction with unrelated proteins

To determine which bands represent genuine ISL2:

• Run ISL2 knockout/knockdown controls in parallel

• Perform peptide competition assays to identify specific bands

• Use antibodies targeting different epitopes to confirm consistent banding patterns

• Compare observed molecular weights with predicted values (ISL2: 39.8 kDa)

• Consider pre-adsorption with recombinant ISL1 to reduce cross-reactivity

What technical considerations are important for reproducible ISL2 immunofluorescence experiments?

Reproducible immunofluorescence for nuclear transcription factors like ISL2 requires attention to several technical aspects:

• Fixation and permeabilization:

  • 4% paraformaldehyde fixation (10-15 minutes) preserves antigenicity

  • Adequate permeabilization (0.1-0.3% Triton X-100) ensures nuclear access

  • Avoid methanol or acetone fixation, which may disrupt epitopes for some ISL2 antibodies

• Signal-to-noise optimization:

  • Titrate antibody concentration (typically 1:100-1:500)

  • Increase blocking duration (1-2 hours) with 5-10% serum

  • Include 0.1-0.3% Tween-20 in wash buffers

• Nuclear counterstaining:

  • Always include DAPI or Hoechst for nuclear visualization

  • Confirm nuclear localization of ISL2 signal

  • Use Z-stack imaging to avoid false negatives from focal plane issues

• Standardization across experiments:

  • Maintain consistent exposure settings between samples

  • Include reference samples across experiments

  • Document all protocol parameters and imaging settings

How can ISL2 antibodies be utilized in chromatin immunoprecipitation (ChIP) experiments?

ChIP experiments using ISL2 antibodies can identify downstream target genes and regulatory networks:

• Antibody selection criteria for ChIP:

  • Select antibodies validated specifically for ChIP applications

  • Prefer antibodies recognizing native (non-denatured) ISL2

  • Consider using monoclonal antibodies for higher specificity

  • Confirm nuclear epitope accessibility in chromatin context

• Protocol optimization:

  • Crosslink with 1% formaldehyde (10 minutes)

  • Use sonication to fragment chromatin (200-500 bp fragments)

  • Optimize antibody concentration (typically 2-5 μg per ChIP reaction)

  • Include appropriate controls (IgG, input DNA, positive locus)

• Data validation approaches:

  • Perform qPCR on putative target genes before proceeding to sequencing

  • Compare binding sites with known ISL2 consensus sequences

  • Validate functional relevance through expression studies

  • Integrate with transcriptomic data from ISL2 perturbation experiments

What considerations apply when using ISL2 antibodies in neuronal differentiation studies?

When studying neuronal differentiation with ISL2 antibodies:

• Temporal sampling strategy:

  • Design experiments with appropriate time points based on model system

  • Include early time points to capture initial ISL2 expression

  • Sample at regular intervals to track expression dynamics

• Co-staining approaches:

  • Combine ISL2 with early progenitor markers (SOX2, PAX6)

  • Include pan-neuronal markers (TUJ1, MAP2)

  • Add motor neuron-specific markers (HB9, ChAT) for subtype identification

  • Consider LIM-code markers to distinguish motor neuron subtypes

• Quantification methods:

  • Develop consistent counting criteria (intensity thresholds)

  • Use automated image analysis for unbiased quantification

  • Report both percentage of positive cells and expression intensity

  • Consider single-cell approaches for heterogeneity assessment

• Differentiation protocol validation:

  • Compare ISL2 expression timing with published developmental timelines

  • Assess co-expression patterns with other transcription factors

  • Validate with functional assays (electrophysiology, axon growth)

What emerging technologies complement ISL2 antibody-based detection methods?

Several cutting-edge approaches enhance traditional ISL2 antibody applications:

• Single-cell proteomics:

  • Mass cytometry (CyTOF) incorporating ISL2 antibodies

  • Antibody-based microfluidic platforms for single-cell protein quantification

  • Integration with single-cell transcriptomics for multi-modal analysis

• High-content imaging:

  • Automated screening using ISL2 antibodies

  • Multiplexed immunofluorescence with cyclic staining or spectral unmixing

  • Machine learning-based image analysis for phenotype classification

• Spatial omics:

  • Combining ISL2 immunostaining with in situ sequencing

  • Spatial transcriptomics correlating with protein expression

  • 3D imaging with tissue clearing and light-sheet microscopy

• Genome editing validation:

  • CRISPR-tagged endogenous ISL2 as antibody validation

  • Epitope-tagged knock-in lines for antibody-independent detection

  • Fluorescent reporter knock-ins for live imaging of ISL2 expression

What information should researchers include when reporting ISL2 antibody experiments?

To enhance reproducibility, researchers should report:

• Antibody details:

  • Vendor name and catalog number

  • Clone designation (for monoclonals)

  • Lot number (particularly important for polyclonals)

  • Host species and antibody type (monoclonal/polyclonal)

  • Target epitope information (when available)

• Validation evidence:

  • Which of the "five pillars" were used for validation

  • Results from knockout/knockdown controls

  • Cross-reactivity assessment, particularly with ISL1

  • Application-specific validation data

• Experimental conditions:

  • Detailed sample preparation protocols

  • Antibody dilutions and incubation conditions

  • Complete staining/detection protocols

  • Image acquisition parameters

  • Quantification and analysis methods

These reporting practices align with guidelines from the International Working Group for Antibody Validation and enhance experimental reproducibility .

How can discrepancies between different ISL2 antibodies be reconciled?

When facing discrepancies between different ISL2 antibodies:

• Epitope analysis:

  • Compare immunogen sequences between antibodies

  • Determine if antibodies target different protein domains

  • Consider epitope accessibility in different applications

• Validation hierarchy:

  • Prioritize results from antibodies validated with knockout controls

  • Consider orthogonal methods (mRNA expression, mass spectrometry)

  • Test for correlation between antibody signal and genetic manipulation of ISL2

• Application-specific performance:

  • Some antibodies may work in WB but not IF (or vice versa)

  • Compare performance across applications

  • Optimize protocols specifically for each antibody

• Consensus approach:

  • Use multiple antibodies targeting different epitopes

  • Look for consistent patterns across antibodies

  • Report discrepancies transparently in publications

These strategies help researchers navigate the complexity of antibody variation and strengthen the validity of their findings.

How might new antibody technologies improve ISL2 detection specificity and sensitivity?

Emerging antibody technologies promise to enhance ISL2 research:

• Recombinant antibody development:

  • Higher batch-to-batch consistency compared to polyclonals

  • Targeted engineering for improved specificity

  • Ability to humanize antibodies for therapeutic applications

  • Custom epitope selection to minimize ISL1 cross-reactivity

• Alternative binder formats:

  • Single-domain antibodies (nanobodies) for improved tissue penetration

  • Aptamers as synthetic alternatives to traditional antibodies

  • Designed ankyrin repeat proteins (DARPins) for higher stability

  • Engineered binding proteins with improved specificity

• Signal amplification methods:

  • Proximity ligation assays for improved sensitivity

  • Click chemistry-based detection systems

  • Branched DNA signal amplification

  • Quantum dot conjugation for photostable detection

• Artificial intelligence applications:

  • AI-assisted epitope selection to maximize specificity

  • Deep learning image analysis for improved signal detection

  • Computational prediction of cross-reactivity